Painel Brasileiro da Obesidade
Hoja de publicación
Nome da publicação: Revisional metabolic and bariatric surgery versus semaglutide: which strategy has greater efficacy for recurrent weigh gain after primary bariatric surgery?
Autores: Yeisson Rivero-Moreno, Arturo Estrada, Diego Zamata-Ovalle, Nawaf Hindosh, Rodolfo Oviedo, Jenny Choi, Erin Moran-Atkin, Diego Camacho
Fuente: Obesity Surgery
Publicado en: 2026
Tipo de archivo: Artigo de periódico
Tipo de estudio: Estudo observacional
Despite metabolic and bariatric surgery (MBS) being the most effective treatment for obesity and its related comorbidities, a significant proportion of patients experience recurrent weight gain (RWG) after primary surgery. In this setting, management options include revisional bariatric surgery (RMBS) and pharmacologic therapy with glucagon-like peptide-1 receptor agonists such as semaglutide. However, comparative data evaluating the effectiveness of both options for the management of RWG after primary MBS remain limited. In this specific cohort of patients with obesity who underwent a primary bariatric procedure and experienced RWG, RMBS was associated with greater weight-loss outcomes compared to semaglutide at 2-year follow-up. The lack of reported safety and complication data for RMBS limits definitive comparisons between management strategies.